Literature DB >> 21382717

Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors.

Hanae Benelkebir1, Christopher Hodgkinson, Patrick J Duriez, Annette L Hayden, Rosemary A Bulleid, Simon J Crabb, Graham Packham, A Ganesan.   

Abstract

Asymmetric cyclopropanation of styrenes by tert-butyl diazoacetate followed by ester hydrolysis and Curtius rearrangement gave a series of tranylcypromine analogues as single enantiomers. The o,- m- and p-bromo analogues were all more active than tranylcypromine in a LSD1 enzyme assay. The m- and p-bromo analogues were micromolar growth inhibitors of the LNCaP prostate cancer cell line as were the corresponding biphenyl analogues prepared from the bromide by Suzuki crosscoupling.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21382717     DOI: 10.1016/j.bmc.2011.02.017

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  24 in total

Review 1.  Small molecule epigenetic inhibitors targeted to histone lysine methyltransferases and demethylases.

Authors:  Zhanxin Wang; Dinshaw J Patel
Journal:  Q Rev Biophys       Date:  2013-09-02       Impact factor: 5.318

2.  Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures.

Authors:  Shannon L Nowotarski; Boobalan Pachaiyappan; Steven L Holshouser; Craig J Kutz; Youxuan Li; Yi Huang; Shiv K Sharma; Robert A Casero; Patrick M Woster
Journal:  Bioorg Med Chem       Date:  2015-02-07       Impact factor: 3.641

3.  Lysine-specific histone demethylase 1 inhibitors control breast cancer proliferation in ERα-dependent and -independent manners.

Authors:  Julie A Pollock; Michelle D Larrea; Jeff S Jasper; Donald P McDonnell; Dewey G McCafferty
Journal:  ACS Chem Biol       Date:  2012-05-10       Impact factor: 5.100

4.  Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.

Authors:  Martin L Schmitt; Alexander-Thomas Hauser; Luca Carlino; Martin Pippel; Johannes Schulz-Fincke; Eric Metzger; Dominica Willmann; Teresa Yiu; Michelle Barton; Roland Schüle; Wolfgang Sippl; Manfred Jung
Journal:  J Med Chem       Date:  2013-09-05       Impact factor: 7.446

Review 5.  KDM1 class flavin-dependent protein lysine demethylases.

Authors:  Jonathan M Burg; Jennifer E Link; Brittany S Morgan; Frederick J Heller; Amanda E Hargrove; Dewey G McCafferty
Journal:  Biopolymers       Date:  2015-07       Impact factor: 2.505

Review 6.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

Review 7.  The role of histone demethylases in cancer therapy.

Authors:  Inga Hoffmann; Martin Roatsch; Martin L Schmitt; Luca Carlino; Martin Pippel; Wolfgang Sippl; Manfred Jung
Journal:  Mol Oncol       Date:  2012-08-07       Impact factor: 6.603

8.  Targeting Histone Demethylases: A New Avenue for the Fight against Cancer.

Authors:  Dante Rotili; Antonello Mai
Journal:  Genes Cancer       Date:  2011-06

9.  New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.

Authors:  Nam Hoang; Xuan Zhang; Chunxiao Zhang; Van Vo; Feng Leng; Lovely Saxena; Feng Yin; Fei Lu; Guangrong Zheng; Pradip Bhowmik; Hui Zhang
Journal:  Bioorg Med Chem       Date:  2018-02-07       Impact factor: 3.641

10.  Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Yuto Mifune; Lijing Su; Hexin Shi; Eva Marie Y Moresco; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Am Chem Soc       Date:  2018-10-16       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.